Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $47.50.
A number of brokerages have recently issued reports on ASMB. Zacks Research raised Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. UBS Group began coverage on Assembly Biosciences in a research report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 target price for the company. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research note on Tuesday, September 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Tuesday, August 18th.
Get Our Latest Research Report on Assembly Biosciences
Assembly Biosciences Stock Performance
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. On average, analysts forecast that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Assembly Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Seven Fleet Capital Management LP purchased a new position in shares of Assembly Biosciences in the 4th quarter worth $147,000. Bank of America Corp DE grew its stake in shares of Assembly Biosciences by 113.3% during the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 5,792 shares during the period. Renaissance Technologies LLC grew its stake in shares of Assembly Biosciences by 69.4% during the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 6,411 shares during the period. Engineers Gate Manager LP increased its position in shares of Assembly Biosciences by 88.5% during the 2nd quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock valued at $488,000 after purchasing an additional 8,343 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $660,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral diseases. The company’s research programs target viral replication and other essential processes, with an emphasis on treatments that may improve outcomes for patients with limited therapeutic options.
Assembly’s pipeline has included investigational therapies for chronic hepatitis B virus (HBV) infection, including core or capsid assembly modulators designed to interfere with the virus’s life cycle.
Featured Stories
- Five stocks we like better than Assembly Biosciences
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
